235 related articles for article (PubMed ID: 15068500)
41. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
Delmas PD; Ensrud KE; Adachi JD; Harper KD; Sarkar S; Gennari C; Reginster JY; Pols HA; Recker RR; Harris ST; Wu W; Genant HK; Black DM; Eastell R;
J Clin Endocrinol Metab; 2002 Aug; 87(8):3609-17. PubMed ID: 12161484
[TBL] [Abstract][Full Text] [Related]
42. Reduction of vertebral fracture risk with raloxifene.
Bashore R
J Fam Pract; 1999 Nov; 48(11):911-2. PubMed ID: 10907630
[No Abstract] [Full Text] [Related]
43. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ
J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
[TBL] [Abstract][Full Text] [Related]
44. [Influence on adjacent lumbar bone density after strengthening of T12, L1 segment vertebral osteoporotic compression fracture by percutaneous vertebroplasty and percutaneous kyphoplasty].
Zhang C; Zhu K; Zhou J; Zhou X; Niu G; Wu M; Shao C
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2013 Jul; 27(7):819-23. PubMed ID: 24063170
[TBL] [Abstract][Full Text] [Related]
45. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
Inaba M
Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
[TBL] [Abstract][Full Text] [Related]
46. [Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Lems WF; Dijkmans BA
Ned Tijdschr Geneeskd; 2000 Oct; 144(41):1941-5. PubMed ID: 11048556
[TBL] [Abstract][Full Text] [Related]
47. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
[TBL] [Abstract][Full Text] [Related]
48. Raloxifene: recent information on skeletal and non-skeletal effects.
Gluck O; Maricic M
Curr Opin Rheumatol; 2002 Jul; 14(4):429-32. PubMed ID: 12118180
[TBL] [Abstract][Full Text] [Related]
49. Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial.
Uusi-Rasi K; Beck TJ; Semanick LM; Daphtary MM; Crans GG; Desaiah D; Harper KD
Osteoporos Int; 2006; 17(4):575-86. PubMed ID: 16392026
[TBL] [Abstract][Full Text] [Related]
50. A comprehensive review of treatments for postmenopausal osteoporosis.
Häuselmann HJ; Rizzoli R
Osteoporos Int; 2003 Jan; 14(1):2-12. PubMed ID: 12577179
[TBL] [Abstract][Full Text] [Related]
51. Prevalent vertebral fractures predict subsequent radiographic vertebral fractures in postmenopausal Korean women receiving antiresorptive agent.
Kim SH; Choi HS; Rhee Y; Kim KJ; Lim SK
Osteoporos Int; 2011 Mar; 22(3):781-7. PubMed ID: 20533028
[TBL] [Abstract][Full Text] [Related]
52. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
[TBL] [Abstract][Full Text] [Related]
53. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
Kushida K; Shiraki M; Nakamura T; Kishimoto H; Morii H; Yamamoto K; Kaneda K; Fukunaga M; Inoue T; Nakashima M; Orimo H
J Bone Miner Metab; 2004; 22(5):462-8. PubMed ID: 15316867
[TBL] [Abstract][Full Text] [Related]
54. Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures.
Nevitt MC; Cummings SR; Stone KL; Palermo L; Black DM; Bauer DC; Genant HK; Hochberg MC; Ensrud KE; Hillier TA; Cauley JA
J Bone Miner Res; 2005 Jan; 20(1):131-40. PubMed ID: 15619679
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.
Kanis JA; Borgström F; Johnell O; Oden A; Sykes D; Jönsson B
Osteoporos Int; 2005 Jan; 16(1):15-25. PubMed ID: 15672210
[TBL] [Abstract][Full Text] [Related]
56. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
[TBL] [Abstract][Full Text] [Related]
57. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
[TBL] [Abstract][Full Text] [Related]
58. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis.
Seeman E; Crans GG; Diez-Perez A; Pinette KV; Delmas PD
Osteoporos Int; 2006 Feb; 17(2):313-6. PubMed ID: 16217588
[TBL] [Abstract][Full Text] [Related]
59. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
60. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
